{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:01:40Z","timestamp":1792292500170,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002908","name":"Stichting Combined Ophthalmic Research Rotterdam","doi-asserted-by":"publisher","award":["4.2.0"],"award-info":[{"award-number":["4.2.0"]}],"id":[{"id":"10.13039\/501100002908","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Uveal melanoma (UM) is an aggressive intra-ocular cancer with a strong tendency to metastasize. Metastatic UM is associated with mutations in <jats:italic>BAP1<\/jats:italic> and <jats:italic>SF3B1,<\/jats:italic> however only little is known about the epigenetic modifications that arise in metastatic UM. In this study we aim to unravel epigenetic changes contributing to UM metastasis using a new genome-wide methylation analysis technique that covers over 50% of all CpG\u2019s. We identified aberrant methylation contributing to <jats:italic>BAP1<\/jats:italic> and <jats:italic>SF3B1<\/jats:italic>-mediated UM metastasis. The methylation data was integrated with expression data and surveyed in matched UM metastases from the liver, skin and bone. UM metastases showed no commonly shared novel epigenetic modifications, implying that epigenetic changes contributing to metastatic spreading and colonization in distant tissues occur early in the development of UM and epigenetic changes that occur after metastasis are mainly patient-specific. Our findings reveal a plethora of epigenetic modifications in metastatic UM and its metastases, which could subsequently result in aberrant repression or activation of many tumor-related genes. This observation points towards additional layers of complexity at the level of gene expression regulation, which may explain the low mutational burden of UM.<\/jats:p>","DOI":"10.1038\/s41598-021-03964-8","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T11:03:34Z","timestamp":1641553414000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Genome-wide aberrant methylation in primary metastatic UM and their matched metastases"],"prefix":"10.1038","volume":"12","author":[{"given":"Kyra N.","family":"Smit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Boers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanda","family":"Vaarwater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Boers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Brands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Mensink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Verdijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfred F. J.","family":"van IJcken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Gribnau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"de Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"key":"3964_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.preteyeres.2018.03.004","volume":"66","author":"B Damato","year":"2018","unstructured":"Damato, B. Ocular treatment of choroidal melanoma in relation to the prevention of metastatic death - A personal view. Prog. Retin. Eye Res. 66, 187\u2013199 (2018).","journal-title":"Prog. Retin. Eye Res."},{"key":"3964_CR2","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.ophtha.2007.01.032","volume":"114","author":"G Virgili","year":"2007","unstructured":"Virgili, G. et al. Incidence of uveal melanoma in Europe. Ophthalmology 114, 2309\u20132315 (2007).","journal-title":"Ophthalmology"},{"key":"3964_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ajo.2009.01.023","volume":"148","author":"JJ Augsburger","year":"2009","unstructured":"Augsburger, J. J., Correa, Z. M. & Shaikh, A. H. Effectiveness of treatments for metastatic uveal melanoma. Am. J. Ophthalmol. 148, 119\u2013127 (2009).","journal-title":"Am. J. Ophthalmol."},{"key":"3964_CR4","doi-asserted-by":"crossref","unstructured":"Smit, K. N., Jager, M. J., de Klein, A. & Kili, E. Uveal melanoma: towards a molecular understanding. Prog. Retin. Eye Res., 100800 (2019).","DOI":"10.1016\/j.preteyeres.2019.100800"},{"key":"3964_CR5","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1126\/science.1194472","volume":"330","author":"JW Harbour","year":"2010","unstructured":"Harbour, J. W. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410\u20131413 (2010).","journal-title":"Science"},{"key":"3964_CR6","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.ophtha.2016.01.023","volume":"123","author":"S Yavuzyigitoglu","year":"2016","unstructured":"Yavuzyigitoglu, S. et al. Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases. Ophthalmology 123, 1118\u20131128 (2016).","journal-title":"Ophthalmology"},{"key":"3964_CR7","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/ng.2674","volume":"45","author":"M Martin","year":"2013","unstructured":"Martin, M. et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat. Genet. 45, 933\u2013936 (2013).","journal-title":"Nat. Genet."},{"key":"3964_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ccell.2017.12.013","volume":"33","author":"AG Robertson","year":"2018","unstructured":"Robertson, A. G. et al. Integrative analysis identifies four molecular and clinical subsets in Uveal melanoma. Cancer Cell 33, 151 (2018).","journal-title":"Cancer Cell"},{"key":"3964_CR9","doi-asserted-by":"crossref","unstructured":"Field, M. G. et al. BAP1 Loss is associated with DNA methylomic repatterning in highly aggressive class 2 Uveal Melanomas. Clin. Cancer Res. (2019).","DOI":"10.1158\/1078-0432.CCR-19-0366"},{"key":"3964_CR10","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1158\/1541-7786.MCR-10-0437","volume":"9","author":"A Calipel","year":"2011","unstructured":"Calipel, A. et al. Status of RASSF1A in uveal melanocytes and melanoma cells. Mol. Cancer Res. 9, 1187\u20131198 (2011).","journal-title":"Mol. Cancer Res."},{"key":"3964_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1136\/bjo.2007.127035","volume":"92","author":"AP Moulin","year":"2008","unstructured":"Moulin, A. P., Clement, G., Bosman, F. T., Zografos, L. & Benhattar, J. Methylation of CpG island promoters in uveal melanoma. Br. J. Ophthalmol. 92, 281\u2013285 (2008).","journal-title":"Br. J. Ophthalmol."},{"key":"3964_CR12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1167\/iovs.06-0781","volume":"48","author":"W Maat","year":"2007","unstructured":"Maat, W. et al. Epigenetic inactivation of RASSF1a in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 48, 486\u2013490 (2007).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"3964_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.tig.2013.11.004","volume":"30","author":"C Stirzaker","year":"2014","unstructured":"Stirzaker, C., Taberlay, P. C., Statham, A. L. & Clark, S. J. Mining cancer methylomes: prospects and challenges. Trends Genet. 30, 75\u201384 (2014).","journal-title":"Trends Genet."},{"key":"3964_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1101\/gr.222885.117","volume":"28","author":"R Boers","year":"2018","unstructured":"Boers, R. et al. Genome-wide DNA methylation profiling using the methylation-dependent restriction enzyme LpnPI. Genome Res. 28, 88\u201399 (2018).","journal-title":"Genome Res."},{"key":"3964_CR15","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1038\/s41467-018-05550-5","volume":"9","author":"M Arechederra","year":"2018","unstructured":"Arechederra, M. et al. Hypermethylation of gene body CpG islands predicts high dosage of functional oncogenes in liver cancer. Nat. Commun. 9, 3164 (2018).","journal-title":"Nat. Commun."},{"key":"3964_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.chembiol.2016.03.017","volume":"23","author":"SM Louie","year":"2016","unstructured":"Louie, S. M. et al. GSTP1 is a driver of triple-negative breast cancer cell metabolism and pathogenicity. Cell Chem. Biol. 23, 567\u2013578 (2016).","journal-title":"Cell Chem. Biol."},{"key":"3964_CR17","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1186\/s12885-015-1926-1","volume":"15","author":"C Fang","year":"2015","unstructured":"Fang, C. et al. Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies. BMC Cancer 15, 920 (2015).","journal-title":"BMC Cancer"},{"key":"3964_CR18","doi-asserted-by":"publisher","first-page":"4358292","DOI":"10.1155\/2016\/4358292","volume":"2016","author":"F Martignano","year":"2016","unstructured":"Martignano, F. et al. GSTP1 methylation and protein expression in prostate cancer: diagnostic implications. Dis. Markers 2016, 4358292 (2016).","journal-title":"Dis. Markers"},{"key":"3964_CR19","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1158\/0008-5472.CAN-16-2589","volume":"77","author":"VK Mishra","year":"2017","unstructured":"Mishra, V. K. et al. Kruppel-like transcription factor KLF10 suppresses TGFbeta-induced epithelial-to-mesenchymal transition via a negative feedback mechanism. Cancer Res. 77, 2387\u20132400 (2017).","journal-title":"Cancer Res."},{"key":"3964_CR20","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.1038\/onc.2017.155","volume":"36","author":"CC Weng","year":"2017","unstructured":"Weng, C. C. et al. KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the Kras(G12D) p53(flox\/flox) model. Oncogene 36, 5532\u20135543 (2017).","journal-title":"Oncogene"},{"key":"3964_CR21","doi-asserted-by":"crossref","unstructured":"Memon, A. & Lee, W. K. KLF10 as a Tumor Suppressor Gene and Its TGF-beta Signaling. Cancers (Basel) 10 (2018).","DOI":"10.3390\/cancers10060161"},{"key":"3964_CR22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ajpath.2012.04.025","volume":"181","author":"VH Chang","year":"2012","unstructured":"Chang, V. H. et al. Kruppel-like factor 10 expression as a prognostic indicator for pancreatic adenocarcinoma. Am. J. Pathol. 181, 423\u2013430 (2012).","journal-title":"Am. J. Pathol."},{"key":"3964_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00441-011-1186-6","volume":"347","author":"B Spittau","year":"2012","unstructured":"Spittau, B. & Krieglstein, K. Klf10 and Klf11 as mediators of TGF-beta superfamily signaling. Cell Tissue Res. 347, 65\u201372 (2012).","journal-title":"Cell Tissue Res."},{"key":"3964_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4149\/neo_2018_180325N201","volume":"66","author":"Q Ji","year":"2019","unstructured":"Ji, Q. et al. KLF11 promotes gastric cancer invasion and migration by increasing Twist1 expression. Neoplasma 66, 92\u2013100 (2019).","journal-title":"Neoplasma"},{"key":"3964_CR25","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s12032-014-0918-3","volume":"31","author":"S Zhang","year":"2014","unstructured":"Zhang, S. et al. Oncogenicity of the transcription factor SOX8 in hepatocellular carcinoma. Med. Oncol. 31, 918 (2014).","journal-title":"Med. Oncol."},{"key":"3964_CR26","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1002\/ijc.31134","volume":"142","author":"SL Xie","year":"2018","unstructured":"Xie, S. L. et al. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt\/beta-catenin pathway. Int. J. Cancer 142, 1252\u20131265 (2018).","journal-title":"Int. J. Cancer"},{"key":"3964_CR27","doi-asserted-by":"publisher","first-page":"35341","DOI":"10.18632\/oncotarget.9241","volume":"7","author":"A Kuhn","year":"2016","unstructured":"Kuhn, A., Loscher, D. & Marschalek, R. The IRX1\/HOXA connection: insights into a novel t(4;11)- specific cancer mechanism. Oncotarget 7, 35341\u201335352 (2016).","journal-title":"Oncotarget"},{"key":"3964_CR28","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1172\/JCI78437","volume":"125","author":"J Lu","year":"2015","unstructured":"Lu, J. et al. IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14\/NF-kappaB signaling. J. Clin. Invest. 125, 1839\u20131856 (2015).","journal-title":"J. Clin. Invest."},{"key":"3964_CR29","doi-asserted-by":"publisher","first-page":"11762","DOI":"10.1038\/s41598-017-12084-1","volume":"7","author":"M Berdasco","year":"2017","unstructured":"Berdasco, M. et al. DNA methylomes reveal biological networks involved in human eye development Functions and Associated Disorders. Sci. Rep. 7, 11762 (2017).","journal-title":"Sci. Rep."},{"key":"3964_CR30","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1101\/gr.131169.111","volume":"22","author":"H Easwaran","year":"2012","unstructured":"Easwaran, H. et al. A DNA hypermethylation module for the stem\/progenitor cell signature of cancer. Genome Res. 22, 837\u2013849 (2012).","journal-title":"Genome Res."},{"key":"3964_CR31","doi-asserted-by":"crossref","unstructured":"Ness, C. et al. Integrated differential DNA methylation and gene expression of formalin-fixed paraffin-embedded uveal melanoma specimens identifies genes associated with early metastasis and poor prognosis. Exp Eye Res 203 (2021).","DOI":"10.1016\/j.exer.2020.108426"},{"key":"3964_CR32","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nature10877","volume":"483","author":"JN Kay","year":"2012","unstructured":"Kay, J. N., Chu, M. W. & Sanes, J. R. MEGF10 and MEGF11 mediate homotypic interactions required for mosaic spacing of retinal neurons. Nature 483, 465\u2013469 (2012).","journal-title":"Nature"},{"key":"3964_CR33","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/mc.22591","volume":"56","author":"J Charlet","year":"2017","unstructured":"Charlet, J. et al. Genome-wide DNA methylation analysis identifies MEGF10 as a novel epigenetically repressed candidate tumor suppressor gene in neuroblastoma. Mol. Carcinog. 56, 1290\u20131301 (2017).","journal-title":"Mol. Carcinog."},{"key":"3964_CR34","doi-asserted-by":"crossref","unstructured":"Huang, M. & Weiss, W. A. Neuroblastoma and MYCN. Cold Spring Harb Perspect Med 3 (2013).","DOI":"10.1101\/cshperspect.a014415"},{"key":"3964_CR35","first-page":"5303","volume":"61","author":"PA van der Velden","year":"2001","unstructured":"van der Velden, P. A. et al. Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res. 61, 5303\u20135306 (2001).","journal-title":"Cancer Res."},{"key":"3964_CR36","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/ijc.11262","volume":"106","author":"PA van der Velden","year":"2003","unstructured":"van der Velden, P. A. et al. Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. Int. J. Cancer 106, 472\u2013479 (2003).","journal-title":"Int. J. Cancer"},{"key":"3964_CR37","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1158\/1078-0432.CCR-07-5144","volume":"14","author":"MD Onken","year":"2008","unstructured":"Onken, M. D., Worley, L. A. & Harbour, J. W. A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis. Clin. Cancer Res. 14, 3737\u20133745 (2008).","journal-title":"Clin. Cancer Res."},{"key":"3964_CR38","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/1471-2407-11-380","volume":"11","author":"LC Neumann","year":"2011","unstructured":"Neumann, L. C. et al. EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation. BMC Cancer 11, 380 (2011).","journal-title":"BMC Cancer"},{"key":"3964_CR39","doi-asserted-by":"publisher","first-page":"59209","DOI":"10.18632\/oncotarget.10962","volume":"7","author":"MG Field","year":"2016","unstructured":"Field, M. G. et al. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas. Oncotarget. 7, 59209\u201359219 (2016).","journal-title":"Oncotarget."},{"key":"3964_CR40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/CMR.0b013e3283005270","volume":"18","author":"SH Chang","year":"2008","unstructured":"Chang, S. H., Worley, L. A., Onken, M. D. & Harbour, J. W. Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res. 18, 191\u2013200 (2008).","journal-title":"Melanoma Res."},{"key":"3964_CR41","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s41588-019-0440-9","volume":"51","author":"AH Shain","year":"2019","unstructured":"Shain, A. H. et al. The genetic evolution of metastatic uveal melanoma. Nat. Genet. 51, 1123\u20131130 (2019).","journal-title":"Nat. Genet."},{"key":"3964_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/01.cco.0000147383.04709.10","volume":"17","author":"M Esteller","year":"2005","unstructured":"Esteller, M. DNA methylation and cancer therapy: new developments and expectations. Curr. Opin. Oncol. 17, 55\u201360 (2005).","journal-title":"Curr. Opin. Oncol."},{"key":"3964_CR43","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1128\/MCB.24.3.1270-1278.2004","volume":"24","author":"JC Cheng","year":"2004","unstructured":"Cheng, J. C. et al. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol. Cell Biol. 24, 1270\u20131278 (2004).","journal-title":"Mol. Cell Biol."},{"key":"3964_CR44","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/modpathol.2017.187","volume":"31","author":"KN Smit","year":"2018","unstructured":"Smit, K. N. et al. Combined mutation and copy-number variation detection by targeted next-generation sequencing in uveal melanoma. Mod. Pathol. 31, 763\u2013771 (2018).","journal-title":"Mod. Pathol."},{"key":"3964_CR45","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/modpathol.2014.43","volume":"27","author":"AE Koopmans","year":"2014","unstructured":"Koopmans, A. E. et al. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Mod. Pathol. 27, 1321\u20131330 (2014).","journal-title":"Mod. Pathol."},{"key":"3964_CR46","doi-asserted-by":"crossref","unstructured":"Smit, K. N. et al. Aberrant MicroRNA Expression and Its Implications for Uveal Melanoma Metastasis. Cancers (Basel) 11 (2019).","DOI":"10.3390\/cancers11060815"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03964-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03964-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03964-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T19:28:19Z","timestamp":1669318099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03964-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3964"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03964-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,7]]},"assertion":[{"value":"13 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest of financial interests except for R.B, J.B., W.V.I. and J.G. who report being shareholder in Methylomics B.V., a commercial company that applies MeD-seq to develop methylation markers for cancer staging.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}